Chimeric Antigen Receptor T-cell (CAR-T cell) therapy has emerged as a groundbreaking treatment for hematologic malignancies, offering hope to patients with relapsed or refractory disease. While CAR-T cell therapy has demonstrated remarkable efficacy in inducing tumor remission, emerging evidence suggests potential neurocognitive changes as a consequence of treatment. In this review, we explore the landscape of neurocognitive changes in patients undergoing CAR-T cell therapy, focusing on the underlying mechanisms, clinical manifestations and implications for patient care. We discuss the multifactorial nature of neurocognitive changes, including Cytokine Release Syndrome (CRS), immune-mediated neurotoxicity and Central Nervous System (CNS) infiltration of CAR-T cells. Furthermore, we examine the challenges in assessing and monitoring neurocognitive function in the context of CAR-T cell therapy and discuss strategies for mitigating cognitive sequelae and improving patient outcomes. By navigating the cognitive terrain, we aim to enhance awareness and understanding of neurocognitive changes associated with CAR-T cell therapy and optimizes supportive care measures for patients undergoing this transformative treatment approach.
HTML PDFShare this article
Journal of Clinical Neurology and Neurosurgery received 2 citations as per Google Scholar report
